Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia.
Saved in:
| Title: | Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia. |
|---|---|
| Authors: | Gil-Rojas Y; Department of Economic Studies, Neuroeconomix, Bogota, Colombia., Lasalvia P; Department of Economic Studies, Neuroeconomix, Bogota, Colombia., García Á; Cardiology Unit, San Ignacio University Hospital, Pontificia Universidad Javeriana, Bogotá, Colombia. |
| Source: | Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2022 Jun; Vol. 22 (4), pp. 655-663. Date of Electronic Publication: 2021 Nov 16. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101132257 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8379 (Electronic) Linking ISSN: 14737167 NLM ISO Abbreviation: Expert Rev Pharmacoecon Outcomes Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1744-8379 |
|---|---|
| DOI: | 10.1080/14737167.2022.1997595 |
